Kornimate/medical-research-clean huggingface dataset:
surgical stabilization of rib fractures while awake or under appropriate sedation by paravertebral block

Conditions: Rib Fracture Multiple; Anesthesia, Local

Summary: tracheal intubation and general anesthesia has been considered a safe and conventional routine methodology for thoracic surgery, include multiple rib fratcure. however,adverse effects such as sore throat, pain, hoarseness, and respiratory complications are common after that. in this study, we decide to perform surgical stabiliazation of rib fractures by paravertebral block surgical stabiliazation of rib fractures under awake or appropriate sedation without endotracheal intubation keeping spontaneous respiration to investigate its safety and feasibility.

rib fracture is common in the world,especially in chest trauma. conservative treatment is used to it for many years but the effect is not well because of continuous pain caused by the dislocation of broken rib. surgical stabiliazation of rib fractures can relieve the pain rapidly and help patient recover to work early. this kind of surgery is constantly conducted with tracheal intubation and general anesthesia. however,adverse effects such as sore throat, pain, hoarseness, and respiratory complications are common after that. so we think perform surgical stabiliazation of rib fractures under awake or appropriate sedation without endotracheal intubation keeping spontaneous respiration to investigate its safety and feasibility.

Eligibility criteria:
inclusion criteria: * simple rib fracutures patients * no other truama * unilatieral rib fractures * total number of rib fractures is less than 5 * at least one rib dislocation * 18-80 years old * asa grade i-ii * bmi\<30 * preoperative arterial partial pressure of oxygen \> 60mmhg * partial pressure of carbon dioxide \< 50mmhg exclusion criteria: * difficult airway * history of esophageal reflux * myasthenia gravis * coagulation disorders * gastrointestinal ulcer * gastrointestinal bleeding * anesthetic drugs allergy history * asthma * chronic obstructive pulmonary disease * pregnant women.
addressing disparities in diabetes care

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this research is to find out if using a continuous glucose monitor and working with a clinical pharmacist can help improve the health of uninsured minority patients with type 2 diabetes.

the objective of this research is to determine the effectiveness of a targeted intervention that integrates continuous glucose monitors and pharmacist-led comprehensive medication management services among uninsured adult patients with poor glycemic control on basal insulin, specifically focusing on black and hispanic populations. this pilot study is designed to help justify implementing this intervention on a larger scale within our healthcare system.

Eligibility criteria:
inclusion criteria: * hispanic or non-hispanic black * diagnosis of type 2 diabetes * hba1c ≥8% within the past 3 months * active prescription for insulin and injecting at least 1 time daily exclusion criteria: * gestational diabetes * type 1 diabetes * receiving care by endocrinologist * continuous glucose monitor use within the past 6 months * receiving long term, hospice, or palliative care services * malignant cancer
comparison of the 6-minute walking test in a corridor and on a non-motorized treadmill

Conditions: Walking, Difficulty

Summary: evaluation of the equivalence of 6-minute walking test performed on a non-motorized treadmill to the reference test : a 6-minute walking test on a corridor.

the six-minute walk test (6-wt) is a standardized test to assess a person's functional ability to walk as far as they can in six minutes. it is widely used in the assessment of functional disability in response to medical intervention in respiratory and cardiac conditions. this test requires a corridor measuring between 20 and 30 metres and does not require any special technical equipment or training. while the test appears simple to set up, factors such as the length or width of the corridor, and external disruptive elements, may affect the results. indeed, the configuration of the test site plays a role in the test result. for example, the distance traveled in a 6-minute walking test is greater on a continuous circuit than in a lane that requires people to walk back and forth or when others are using the lane (zigzags, slowdowns). in a hospital setting, while it is easy to find a corridor that is long enough, it is not always possible to dedicate it exclusively to walking tests. an alternative would be to perform this test on a non-motorized treadmill to avoid these biases. the main objective of this study is to evaluate the equivalence of a 6-minute walking test performed on a non-motorized treadmill to the reference test in healthy subjects. in addition, a small number of patients will be invited to perform a 6-minute ct scan on a non-motorized treadmill in order to first evaluate the perception and acceptability of this new method in this population (seniors, pathologies). if the results are conclusive, a similar study with patients only will be performed.

Eligibility criteria:
inclusion criteria: * healthy subject 18 years of age or older * have signed a consent form * be affiliated with a health insurance plan * having a pathology requiring the monitoring of the evolution of the distance performed by 6-wt (patients only) exclusion criteria: * being unable to walk for several minutes for physical, neurological or psychological reasons * recent acute coronary syndrome * rest tachycardia greater than 120 pulses/min. * resting blood pressure greater than 180/100 mmhg * pregnant, parturient or nursing women * persons deprived of liberty: minors or adults who are subject to a legal protection measure or who are unable to express their consent. * subjects under guardianship or curatorship.

Keywords: 6-minutes walking test; 6-wt
exploratory study of l.s.e.s.r. (lipidosterolic extract of serenoa repens)(permixon® 160 mg hard capsule) versus tamsulosine lp activity on inflammation biomarkers in urinary symptoms related to bph (benign prostatic hyperplasia)

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: inflammation is reported as one of the most recent hypotheses to explain bph. recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation. the aim of the study is to assess the activity on inflammation biomarkers (serum and urine inflammation markers) of permixon® 160 mg hard capsule and tamsulosine arrow lp in the treatment of urinary symptoms related to bph. the potential links between serum and urinary markers of inflammation and bph clinical symptoms at baseline and on treatment will be explored.


Eligibility criteria:
inclusion criteria: * male patient * between 45 and 85 years old. * patient with bothersome lower urinary tract symptoms such as pollakiuria (daytime or night time), urgency, sensation of incomplete voiding, delayed urination or weak stream, existing for over 12 months * i-pss ≥ 10 at selection visit and ≥ 12 at randomisation visit (visit 2) * stable patient's disease at randomisation defined as an absolute difference of 2 or less on i-pss between selection and randomisation visits (visit 1 and visit 2) * i-pss qol score ≥ 3 evaluated at selection and randomisation visits, * 5 ml/s ≤ maximum urinary flow rate \< 15 ml/s for a voided volume ≥ 150 ml and ≤ 500 ml evaluated at randomisation visit (2 measurements if necessary) * prostatic volume ≥30 cm³ determined by transrectal ultrasound at randomisation visit (visit 2) * serum total psa at randomisation visit (visit 2) : * 4 ng/ml * 10 ng/ml and prostate specific antigen (free) / prostate specific antigen (total) ≥ 25% or negative prostate biopsy within the past 6 months prior to selection visit. * patient able to understand and sign the informed consent and understand and fill in self-questionnaires exclusion criteria: * post-void residual urine volume \> 200 ml (by suprapubic ultrasound) at randomisation visit (visit 2). * urological history : * urethral stricture disease and/or bladder neck disease * active (at selection and randomisation visits) or recent (\< 3 months) or recurrent urinary tract infection * indication of bph surgery * stone in bladder or urethra * acute or chronic (documented) prostatitis * prostate and cancer cancer treated or untreated * interstitial cystitis (documented by symptoms and/or biopsy) * active upper tract stone disease causing symptoms * patient with history of surgery of the prostate, bladder neck or pelvic region * any local and/or systemic inflammation disorders at selection and randomisation visit
observational study relapsed or refractory chronic lymphocytic leukemia venetoclax-based regimens outside clinical trials in italy

Conditions: Chronic Lymphocytic Leukemia; Relapse Leukemia; Refractory Leukemia

Summary: observational study aimed at describing the characteristics and outcome of cll patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in italy in a period of time ranging from the start of the venetoclax named patient program (march 2016) until june 30th, 2025.

observational study to describe the characteristics and outcome of cll patients treated with venetoclax according to the local label. the study includes two different groups: a retrospective group (all patients who have received at least one dose of venetoclax before enrolment) and a prospective group (patients receiving treatment with venetoclax after enrolment). all patients in both groups will be observed for up to 48 months from the treatment start. in the prospective cohort only, qol and treatment adherence will be assessed at the time of study entry (i.e. baseline) and thereafter at 3, 6, 9, 12, 18 24, 30, 36, 42 and 48 months of follow-up and at treatment discontinuation (due to any cause).

Eligibility criteria:
inclusion criteria 1. patients with r/r cll fulfilling the eligibility criteria required by the venetoclax named patient program who have received at least 1 dose of venetoclax. 2. patients with cll who have received at least 1 dose of venetoclax or are scheduled to start treatment with venetoclax according to the post-marketing use before june 30th, 2025. 3. signed informed consent document (if feasible) according to ich/eu/gcp and national local laws indicating that the patients understand the purpose of the study and they agree to give complete access to their medical records. exclusion criteria: none
the effect of januvia (sitagliptin) on oxidative stress in obese type 2 diabetic subjects

Conditions: Type 2 Diabetes

Summary: sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. sitagliptin has been shown to have fewer side effects in the control of blood glucose values. obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. in this study we want to see the effect of sitagliptin on these markers. we believe that sitagliptin may exert an anti-inflammatory effect in the human. the purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. we believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.


Eligibility criteria:
inclusion criteria: * males or females with age 20-75 years inclusive. * type 2 diabetes * males and females bmi \> 30 * subjects on statins, ace inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study. * bp under control -no change required to bp medications * hba1c \> 7% exclusion criteria: * coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks * pregnancy * hepatic disease (abnormal lft's),renal impairment (serum creatinine \> 1.5), * participation in any other concurrent clinical trial * any other life-threatening, non-cardiac disease, * uncontrolled hypertension (bp \> 160/100 mm of hg) * congestive heart failure * use of an investigational agent or therapeutic regimen within 30 days of study * subjects on exenatide, incretin or insulin therapy
ulnar wrist pain treatment with dextrose prolotherapy

Conditions: Ulnar Wrist Pain

Summary: participants who have failed therapy for chronic wrist pain on the little finger side of the wrist will recieve dextrose prolotherapy. their results will be compared to a cohort of consecutive participants who have not failed therapy, and receive 4 weeks of usual care.


Eligibility criteria:
inclusion criteria * pain on the ulnar side of the wrist. * prwe greater than 40 exclusion criteria * radioulnar instability more than moderate as determined by a positive ulna fovea sign or ulna grinding test * surgery in the wrist area * infection in the wrist area * other wrist pathology on examination * other pain area that is constant, interferes with sleep, or is as bad, or worse, than shoulder pain. * diabetes or other peripheral neuropathy * radiculopathy * unstable psychiatric function. * current opioid use. * vulnerable patients * pregnancy

Keywords: tendinopathy wrist chronic pain sprain
open-label extension study of recombinant human arylsulfatase a (hgt-1111) in late infantile mld

Conditions: Late Infantile Metachromatic Leukodystrophy

Summary: this is a multi-center, open-label, extension study of patients with late infantile mld who have previously completed clinical study hgt-mld-048 (nct00633139), defined as the completion of all week 52 procedures. this group of patients will be offered ongoing treatment with hgt-1111 in this protocol. one infusion will be given every other week until the product is commercially available, the patient discontinues, or the study is terminated by the sponsor, provided no safety issues have emerged.

the primary objective of this study is to provide ongoing treatment of hgt-1111 to patients who have completed study hgt-mld-048 (previously study rhasa-03 - nct00633139) until hgt-1111 is commercially available or the study is terminated by the sponsor, provided no safety concerns have emerged. the secondary objective of this study is to monitor disease progression and the safety profile of hgt-1111 administered to patients who have completed study hgt-mld-048 (nct00633139).

Eligibility criteria:
inclusion criteria: 1. subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject) 2. completion of study hgt-mld-048 (nct00633139) 3. the subject and his/her guardian(s) must have the ability to comply with the protocol exclusion criteria: 1. spasticity so severe to inhibit transportation 2. presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that, in the opinion of the investigator, would preclude participation in the trial 3. any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial

Keywords: metazyme late infantile metachromatic leukodystrophy
the effects of different types of music on patients undergoing thyroid surgery

Conditions: Thyroid

Summary: this study was conducted to investigate the effect preoperative music interventions on anxiety and postoperative comfort level in patients.

objective: this study was conducted to investigate the effect of preoperative music interventions on anxiety and postoperative comfort levels in patients. design: a randomized controlled quasi-experimental design was used. methods: this study was conducted in the general surgery clinic of a university hospital in diyarbakır, turkey. a total of 100 patients (47 in the intervention and 53 in the control group) participated in the study by randomization. personal information form, hemodynamic parameters, and state-trait anxiety inventory were used for data collection. the state part of the state-trait anxiety inventory was re-administered to the intervention group after the music intervention. in the postoperative period, hemodynamic parameters of all patients in both groups were monitoredş and the perianesthesia comfort questionnaire was administered. spss 25.0 software was used for data analysis.

Eligibility criteria:
inclusion criteria: * ages of 18-65, * hospitalized for 24 hours after surgery, * without cognitive impairment * consenting to participate exclusion criteria: * individuals under the age of 18 and over the age of 65 * individuals with cognitive impairment * individuals who declined to participate in the study

Keywords: anxiety thyroidectomy music patient comfort
observational registry on long-term outcome of icd patients

Conditions: Cardiomyopathies

Summary: multicentric, observational, retrospective registry including patients underwent icd implantation for any indication. the primary aim of the registry is to evaluate the long-term outcome of patients receiving an icd.

multicentric, observational, retrospective registry including patients underwent icd implantation for any indication in the period from 2010 to 2012. the aims of the registry are to evaluate the occurrence of complications related to icd implantation (including icd shocks and electrical storm), and the mortality during a long-term follow-up.

Eligibility criteria:
inclusion criteria: * icd implantation fo any indication; * age \>18 years exclusion criteria: * life expectancy of less than one year

Keywords: implantable defibrillator cardiomyopathies
femoral cartilage thickness in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of the study to investigate the relationship between femoral cartilage thickness in ultrasonographic evaluation and inflammatory parameters, pain severity and functionality in participants with knee osteoarthritis

aim: the aim of the study is to investigate the relationship between femoral cartilage thickness and inflammatory parameters, pain severity and functionality in participants with knee osteoarthritis. methods: this study is designed as a prospective, cross-sectional trial. 90 participants aged between 50-65 years with knee osteoarthritis(oa) and at least 50 participants without any symptom for knee oa are included in the study in accordance with the inclusion criteria. participants' demographic characteristics will be evaluated, and ultrasonographic measurement will be performed for measuring femoral cartilage thickness. visual analog scale will be used for pain severity and western ontario and mcmaster universities osteoartrit index (womac) will be used for assessing functionality of the patients. also hematologic parameters(neutrophils, leucocytes, lymphocytes, platelet, crp, erythrocyte sedimentation rate) will be evaluated for investigating the inflammation. the relationship between femoral cartilage thickness and inflammatory parameters, pain severity and functionality in knee osteoarthritis will be analysed for both group.

Eligibility criteria:
inclusion criteria: * diagnosed as knee osteoarthritis * aged between 50-65 years * volunteer to participate in the study exclusion criteria: * limitation of cooperation * moderate to severe dementia or mental retardation, which may cause limitations in examination, testing and treatment * refusal to participate in the study * pprevious total knee prosthesis surgery * secondary osteoarthritis
learner- low dose aspirin preterm trial (angola)

Conditions: Sickle Cell Disease; Pregnancy Related; Pregnancy Complications; Pre-Eclampsia

Summary: this study is being conducted to evaluate the safety and effect of starting daily use of low dose (100 mg) aspirin in pregnant women with sickle cell disease, who are being followed in two county hospitals in angola, in the first trimester versus the second trimester of the gestational period.

the proposed project is a prospective, randomized controlled study to evaluate the effects of daily low dose aspirin in pregnant women with sickle cell disease at the first trimester versus the second trimester of the gestation period. the study will include 450 female participants of all ages, in multiple maternity hospitals in luanda, angola, with an official diagnosis of sickle cell disease and confirmed pregnancy. patients who consent to take part in the study will be given 100 mg aspirin once daily either at the first trimester (6-13 weeks) or the second trimester (14-27 weeks) of the gestation period. up to 450 participants will be randomly assigned in a 1:1 ratio to the two study treatment trimester groups (225 starting the low dose of aspirin at the first trimester and 225 starting the low dose of aspirin at the second trimester). in both treatment arms, daily use of low dose aspirin will be prescribed/administered until week 36 or time of delivery, whichever comes earlier. study duration: each participant will be enrolled in the study for the duration of the pregnancy as follow: screening visit randomized treatment period follow up period (6 weeks postpartum)

Eligibility criteria:
inclusion criteria: * 1. pregnant women with sickle cell disease 15 years old and older * 2. attending maternidade lucrecia paim, hospital materno infantil dr. manuel pedro azancot de menezes, or any health commodities in the neighboring area of the referred hospitals * 3. willing to attend the regular consultations, and consent to take part in the study. exclusion criteria: * 1. pregnant women with sickle cell disease in the third trimester (after week 27) * 2. hiv infection * 3. diabetes mellitus * 4. chronic hypertension * 5. liver disease measured by laboratory indication being 3 times above the upper limit of normal * 6. sickle nephropathy * 7. multiple pregnancies * 8. hypersensitivity to aspirin * 9. history of blood transfusion in the last 3 months * 10.those who did not consent to participate in the study.

Keywords: learner angola maternidade lucrécia paim hospital materno infantil dr manuel pedro azancot de menezes aspirin capacity building